scholarly journals Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882391 ◽  
Author(s):  
Sharad Khurana ◽  
Salman Ahmed ◽  
Victoria R Alegria ◽  
Sonikpreet Aulakh ◽  
Meghna Ailawadhi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Partial Remission ◽  
Single Agent ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Viable Option ◽  
Leukemia Patient ◽  
Therapeutic Landscape ◽  
Response Status ◽  
Anti Cd20

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2.5 years. After retreatment with single-agent obinutuzumab, the patient achieved a partial remission again within one cycle and continues to maintain the response status. This case is a platform for considering obinutuzumab as a viable option for retreatment of chronic lymphocytic leukemia patients who have received it before, similar to the pattern of use for other anti-CD20 monoclonal antibodies in this disease, including rituximab.

Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis

2017 ◽  
pp. 127-138 ◽  
Author(s):  
Eleftheria Polychronidou ◽  
Aliki Xochelli ◽  
Panagiotis Moschonas ◽  
Stavros Papadopoulos ◽  
Anastasia Hatzidimitriou ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Somatic Hypermutation ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

Expression of a receptor for sheep erythrocytes by B lymphocytes from a chronic lymphocytic leukemia patient

1983 ◽  
Vol 27 (2) ◽  
pp. 210-222 ◽  
Author(s):  
Roberto Sitia ◽  
Luca Sciariada ◽  
Antonio Zicca ◽  
Arnaldo Leprini ◽  
Riccardo Ghio ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Sheep Erythrocytes ◽  
Leukemia Patient

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Blood ◽  
2008 ◽  
Vol 111 (3) ◽  
pp. 1094-1100 ◽  
Author(s):  
Bertrand Coiffier ◽  
Stéphane Lepretre ◽  
Lars Møller Pedersen ◽  
Ole Gadeberg ◽  
Henrik Fredriksen ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Partial Remission ◽  
Phase 1 ◽  
Objective Response ◽  
Median Number ◽  
Maximum Tolerated Dose ◽  
Lymphocytic Leukemia ◽  
Safety And Efficacy ◽  
Anti Cd20

Abstract Safety and efficacy of the fully human anti-CD20 monoclonal antibody, ofatumumab, was analyzed in a multicenter dose-escalating study including 33 patients with relapsed or refractory chronic lymphocytic leukemia. Three cohorts of 3 (A), 3 (B), and 27 (C) patients received 4, once weekly, infusions of ofatumumab at the following doses: (A) one 100 mg and three 500 mg; (B) one 300 mg and three 1000 mg; (C) one 500 mg and three 2000 mg. Sixty-seven percent of the patients were Binet stage B, and the median number of previous treatments was 3. The maximum tolerated dose was not reached. The majority of related adverse events occurred at first infusion, and the number of adverse events decreased at each subsequent infusion. Seventeen (51%) of 33 patients experienced infections, 88% of them of grade 1-2. One event of interstitial pneumonia was fatal; all other cases resolved within one month. The response rate of cohort C was 50% (13/26), one patient having a nodular partial remission and 12 patients partial remission. In conclusion, ofatumumab was found to be well tolerated in patients with chronic lymphocytic leukemia (CLL) in doses up to 2000 mg. Preliminary data on safety and objective response are encouraging and support further studies on the role of ofatumumab in CLL patients. This trial was registered at www.clinicaltrials.gov as no. NCT00093314.

Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient

2008 ◽  
Vol 32 (2) ◽  
pp. 363-365 ◽  
Author(s):  
Pasquale Niscola ◽  
Maria Ilaria Del Principe ◽  
Massimiliano Palombi ◽  
Stefano Fratoni ◽  
Daniela Piccioni ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient ◽  
Cell Chronic Lymphocytic Leukemia

Central Nervous System Expression of a Monoclonal Paraprotein in a Chronic Lymphocytic Leukemia Patient

1992 ◽  
Vol 88 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Phillip Ruiz ◽  
Manijeh Moezzi ◽  
Wilfredo Chamizo ◽  
Parvin Ganjei ◽  
Clarence C. Whitcomb ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient
Sign in / Sign up

Export Citation Format

Share Document